Tags : the EC

Novartis’ Enerzair Breezhaler Receives the EC’s Approval as a Maintenance

Shots: The approval is based on P-III IRIDIUM study assessing Enerzair Breezhaler (qd) vs Atectura Breezhaler (QMF149; IND/MF) in 3092 patients in the ratio (1:1:1:1) whose asthma is uncontrolled with LABA/ICS SOC treatment which resulted in improvement of ACQ-7 score @26wks., reductions in asthma exacerbation rates were observed in moderate-to-severe and safety profile was consistent […]Read More